Periostin in bronchial asthma – a brief update
##plugins.themes.bootstrap3.article.main##
##plugins.themes.bootstrap3.article.sidebar##
Abstract
Periostin is an extracellular matrix protein which intervenes in the regulation of angiogenesis, and in tumoral cells proliferation and invasion. Recent studies, mainly experimental models, have demonstrated the intervention of this molecule in asthmatic disease, by eosinophils recruitment, bronchial wall remodeling, and by stimulation of inflammatory cytokines production. Currently, periostin is considered a marker of type 2 inflammation in asthma, being secreted by respiratory epithelial cells triggered by IL-13 and IL-4. Concomitantly, periostin accumulated at the bronchial epithelial-connective tissue interface is involved in fibrogenesis and mucus secretion, in correlation with the intensity of bronchial mucosa eosinophilic inflammatory infiltrate. However, the intimate molecular mechanisms of periostin involvement in the pathogenic pathway of asthmatic diseases is far away from elucidation, further research being necessary to certify its value as a biomarker useful in diagnosis and in establishment of therapeutic schemes in bronchial asthma.
##plugins.themes.bootstrap3.article.details##
periostin, bronchial asthma, allergic inflammation
2. Maruhashi T, Kii I, Saito M, et al. Interaction between periostin and BMP-1 promotes proteolytic activation of lysyloxidase. J Biol Chem 2010; 285(17):13294-13303.
3. Kii I, Nishiyama T, Li M, et al. Incorporation of tenascin-C into the extracellular matrix by periostin underlies an extracellular meshwork architecture. J Biol Chem 2010; 285 (3):2028-2039.
4. Nuzzo PV, Buzzatti G, Ricci F, et al. Periostin: a novel prognostic and therapeutic target for genitourinary cancer? Clin Genitourin Cancer 2014; 12(5):301–311.
5. Conway SJ, Izuhara K, Kudo Y, et al. The role of periostin in tissue remodeling across health and disease. Cell Mol Life Sci 2014; 71(7):1279–1288.
6. Zhu M, Fejzo MS, Anderson L, et al. Periostin promotes ovarian cancer angiogenesis and metastasis. Gynecol Oncol 2010; 119(2):337–344.
7. Kusumoto D, Fukuda K. The role of angiogenetic factors in the pathogenesis and the progression of cardiac valve disease. Clin Calcium 2013; 23(4):481–488.
8. Idolazzi L, Ridolo E, Fassio A, et al. Periostin: The bone and beyond. Eur J Intern Med 2016; S0953-6205(16)30412-5.
9. Izuhara K, Arima K, Ohta S, et al. Periostin in allergic inflammation. Allergol Int 2014; 63(2):143–151.
10. Arima K, Ohta S, Takagi A, et al. Periostin contributes to epidermal hyperplasia in psoriasis common to atopic dermatitis. Allergol Int 2015; 64(1):41–48.
11. Rothenberg ME, Wen T, Greenberg A, et al. Intravenous anti-IL-13 mAb QAX576 for the treatment of eosinophilic esophagitis. J Allergy Clin Immunol 2015; 135(2):500-507.
12. Li W, Gao P, Zhi Y, et al. Periostin: its role in asthma and its potential as a diagnostic or therapeutic target. Respir Res 2015; 16:57.
13. Izuhara K, Ohta S, Ono J. Using Periostin as a Biomarker in the Treatment of Asthma. Allergy Asthma Immunol Res 2016; 8(6):491-498.
14. Palme S, Christenson RH, Jortani SA, et al. Multicenter evaluation of analytical characteristics of the Elecsys® Periostin immunoassay. Clin Biochem 2016; S0009-9120(16)30376-9.
15. Takayama G, Arima K, Kanaji T, et al. Periostin: A novel component of subepithelial fibrosis of bronchial asthma downstream of IL-4 and IL-13 signals. J Allergy Clin Immunol 2006; 118(1):98-104.
16. Kanemitsu Y, Matsumoto H, Mishima M, et al. Factors contributing to an accelerated decline in pulmonary function in asthma. Allergol Int 2014; 63(2):181–188.
17. Parulekar AD, Atik MA, Hanania NA. Periostin, a novel biomarker of TH2-driven asthma. Curr Opin Pulm Med 2014; 20(1):60–65.
18. Johansson MW, Annis DS, Mosher DF. αMβ2 integrin-mediated adhesion and motility of IL-5-stimulated eosinophils on periostin. Am J Respir Cell Mol Biol 2013; 48(4):503–510.
19. Jeanblanc NM, Hemken PM, Datwyler MJ, et al. Development of a new ARCHITECT automated periostin immunoassay. Clin Chim Acta 2017; 464:228-235.
20. Matsusaka M, Kabata H, Fukunaga K, et al. Phenotype of asthma related with high serum periostin levels. Allergol Int 2015; 64(2):175-180.
21. Wesolowska-Andersen A, Seibold MA. Airway molecular endotupes of asthma: dissecting the heterogeneity. Cur Opin Allergy Clin Immunol 2015; 15(2):163-168.
22. Tartibi HM, Bahna SL. Clinical and biological markers of asthma control. Expert Rev Clin Immunol 2014; 10(11):1453–1461.
23. Pappas K, Papaioannou AI, Kostikas K, et al. The role of macrophages in obstructive airways disease: chronic obstructive pulmonary disease and asthma. Cytokine 2013; 64(3):613–625.
24. Gordon ED, Sidhu SS, Wang ZE, et al. A protective role for periostin and TGF-beta in IgE-mediated allergy and airway hyperresponsiveness. Clin Exp Allergy 2012; 42(1):144–155.
25. Bentley JK, Chen Q, Hong JY, et al. Periostin is required for maximal airways inflammation and hyperresponsiveness in mice. J Allergy Clin Immunol 2014; 134(6):1433–1442.
26. Sidhu SS, Yuan S, Innes AL, et al. Roles of epithelial cell-derived periostin in TGF-beta activation, collagen production, and collagen gel elasticity in asthma. Proc Natl Acad Sci U S A 2010; 107(32):14170–14175.
27. Johansson MW, Mosher DF. Integrin activation States and eosinophil recruitment in asthma. Front Pharmacol 2013; 4:33.
28. Choi JH, Kim MA, Park HS. An update on the pathogenesis of the upper airways in aspirin-exacerbated respiratory disease. Curr Opin Allergy Clin Immunol 2014; 14(1):1–6.
29. Foster PS, Hogan SP, Ramsay AJ, et al. Interleukin 5 deficiency abolishes eosinophilia, airways hyperreactivity, and lung damage in a mouse asthma model. J Exp Med 1996; 183(1):195–201.
30. Kips JC, O'Connor BJ, Langley SJ, et al. Effect of SCH55700, a humanized anti-human interleukin-5 antibody, in severe persistent asthma: a pilot study. Am J Respir Crit Care Med 2003; 167(12):1655–1659.
31. Tartibi HM, Bahna SL. Clinical and biological markers of asthma control. Expert Rev Clin Immunol 2014; 10(11):1453–1461.
32. Corren J, Lemanske RF, Hanania NA, et al. Lebrikizumab treatment in adults with asthma. N Engl J Med 2011; 365(12):1088–1098.
33. Arron JR, Izuhara K. Asthma biomarkers: what constitutes a 'gold standard'? Thorax 2015; 70(2):105-7.
34. Sehra S, Yao W, Nguyen ET, et al. Periostin regulates goblet cell metaplasia in a model of allergic airway inflammation. J Immunol 2011; 186(8):4959–4966.
35. Li BL, Hou JJ, Nie FF, et al. Variations in expressions of periostin and related factors in early stage of wound healing and scar remodeling in rats. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue 2013; 25(9):523–526.
36. Song JS, You JS, Jeong SI, et al. Serum periostin levels correlate with airway hyper-responsiveness to methacholine and mannitol in children with asthma. Allergy 2015; 70(6):674–681.
37. Konradsen JR, Skantz E, Nordlund B, et al. Predicting asthma morbidity in children using proposed markers of Th2-type inflammation. Pediatr Allergy Immunol 2015; 26(8):772–779.
Archive of Clinical Cases is protected by copyright and may be used in accordance with copyright and other applicable laws. Content available at www.clinicalcases.eu and our digital applications is intended for personal noncommercial use.
Authors who submit a manuscript for publication in Archive of Clinical Cases agree to the following terms: a. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal. b. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal. c. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) only after the final version of the manuscript was accepted and published, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access). d. It is compulsory that before submission authors ensure that their work was not published in any other medical journals or pending acceptance for publication and that "Archives of Clinical Cases" is the only beneficiary at that moment if their work/case will be accepted by us.
Guidelines for linking to www.clinicalcases.eu a. The main purpose of the site linking to the Archive of Clinical Casess site should be educational. b. Links should be made to the Archive of Clinical Casess home page (www.clinicalcases.eu) or to the articles abstract. c. It is forbidden to use the Archive of Clinical Casess cover by outside organizations unless permission has been granted in advance, notifying our Secretary. d. Material owned by the Archive of Clinical Cases (including the name, logo, cover, and text) may not be used in any manner that may induce the idea or suggest that the Archive of Clinical Cases is in some way recommending a specific company, product or service. e. You must not use or allow others to access or use, all or any part of our Site or the contents and/or applications on it for commercial purposes without our permission. To seek permission to do anything prohibited by or not contained in these TERMS, or which requires our prior consent or agreement, you can contact us.